»ªÖпƼ¼´óѧͬ¼ÃҽѧԺ2003Äê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ
s#~GH6/
Mips.Bx
¿¼ÊÔ¿ÆÄ¿£ºÒ½Ñ§ÃâÒßѧ£¨»ù´¡¿Î£©¿ÆÄ¿´úÂ룺806 ^DeERB
fWfk[(M'9
Ò»Ãû´Ê½âÊÍ£¨¹²5Ì⣬ÿÌâ4·Ö£¬¹²20·Ö£© (.wIe/
1.Antigen presenting cell£¨APC£© `nM/l@
2.Activation induced cell death£¨AICD£© O/AaYA&
3.Chemokine IN8>ZV`j)
4.Major histocompatibility complex£¨MHC£© w
N
1niR'
5.immunotolerance x-OA([;/
CYYkzcc^
¶þÎÊ´ðÌ⣨¹²5Ì⣬ÿÌâ10·Ö£¬¹²50·Ö£© _vSn`
1.ÊÔÊö²ÎÓëThϸ°ûÓëBϸ°ûÏ໥¼¤»îµÄ·Ö×Ó¼°¸÷×ԵŦÄÜ ?0?
R
2.ºÎν𤸽·Ö×Ó£¿¼òÊö𤸽·Ö×ӵķÖÀ༰ÆäÔÚÃâÒßÖеÄ×÷Óà B`*ZsS=R-
3.¼òÊöIIÐͳ¬Ãô·´Ó¦µÄ·¢Éú»úÖÆ JD@J[YY5R
4.ÔÚÕý³£Çé¿öÏ£¬ÃâÒßϵͳ¶Ô×ÔÉí¿¹Ô²»²úÉúÃâÒßÓ¦´ðµÄ»úÖÆÊÇʲô£¿ kB?al#`
5.±È½ÏCTLºÍNKɱÉ˰Ðϸ°ûʱʶ±ðºÍɱÉË»úÖÆµÄÌØµã 8Ac)'2t;U
O"Ku1t!
ÈýÑ¡´ðÌ⣨µÚ1Ìâ±Ø´ð£¬2ºÍ3ÌâÈÎÑ¡1Ì⣬ÿÌâ15·Ö£¬¹²30·Ö£© d>;&9;)H
1.¼òÊöÒÆÖ²ÅųⷴӦÖÐÊÜÕßTϸ°û¶ÔͬÖÖÒìÌ忹ԵÄʶ±ð»úÖÆ¡£Í¨¹ýÖ±½Óʶ±ð¼¤»îµÄÊÜÕßThϸ°ûºÍTcϸ°û·Ö±ðÔÚ¸¨ÖúÊÜÕßBϸ°ûºÍɱÉËÒÆÖ²Îï·½ÃæÓë¼ä½Óʶ±ð¼¤»îµÄThºÍTcÓкβîÒ죿Ϊʲô£¿ 06$!R/K
2.½áºÏÄãµÄרҵÊÔÊöϸ°ûÒò×ÓÔÚ¼²²¡·¢Éú·¢Õ¹ÖеÄ×÷Óã¬Ä㽫²ÉÈ¡ÄÄЩ²ßÂÔÕë¶ÔÕâЩ°ÐµãÖÎÁƼ²²¡£¿ C<KrMRWh^
3.ºÎΪ»ùÒò¹¤³Ì¿¹Ì壿Ŀǰ¹úÄÚÍâÔÚ»ùÒò¹¤³Ì¿¹ÌåÑо¿ÖÐÓÐÄÄЩÖ÷Òª½øÕ¹£¿ ono4U.C9
x77l~=P+!
»ªÖпƼ¼´óѧͬ¼ÃҽѧԺ2003Äê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ WVVJ
Q+g!V5'
¿¼ÊÔ¿ÆÄ¿£ºÒ½Ñ§ÃâÒßѧ£¨×¨Òµ¿Î£©¿ÆÄ¿´úÂ룺906 afYc\-"
M\yT).>z
Ò»Ãû´Ê½âÊÍ£¨4·Ö/Ì⣩ 9U$EJN_G
1.Antigenic determinant c478P=g=5
2.IgSF {?'fyEeg
3.MBL;¾¶ LpR3BP@At
4.chemokine ^]{R.(#z
5.HLA¸´ºÏÌåµÄ¶à»ùÒòÐÔÓë¶àëÄÐÔ } CeCc0M
6.TCR-CD3¸´ºÏÎï G:zua`u[
7.FADD£¨Fas-associated protein with death domain£© 2W4qBaG$=
8.AIDS ~gGZmTb
9.Tumor rejection antigen {&"N%;`Q
10.AICD o6V}$wT3J
=i~}84>
¶þÎÊ´ðÌ⣨15·Ö/Ì⣩ Yo[;W
vu
1.¼òÊöCD·Ö×ÓÔÚÃâÒßЧӦÖеÄ×÷Ó㨰´ÊÜÌå·ÖÀà¼òÊö£© OE}*2P/M>
2.¼òÊöBϸ°û²ÎÓëµÄÃâÒß¹¦ÄÜ \Gc+WpS(
3.¼òÊö×ÔÉíÃâÒßÐÔ¼²²¡Ê±Õë¶Ô×ÔÉí×éÖ¯²úÉúÃâÒßÓ¦´ðµÄ¿ÉÄÜ»úÖÆ 4'0Dr++
4.ºÎνͬÖÖÒìÐÍMHC¿¹ÔÖ±½Óʶ±ðºÍ¼ä½Óʶ±ð£¿¼òÊöÆäÒì 8MSC.0
Th=eNL]
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾Å¶þÄê¹¥¶Á˶ʿÑо¿ÉúÈëѧÊÔÌâ uDEvzk42
}Hn/I,/
fMOU$0]$<
רҵ¿Î ÃâÒßѧ rwGKfoKI
Ò»¡¢ ·Òë²¢½âÊÍÏÂÁÐÃû´Ê 8QM(?A
1. Immunotoxin 2. T inducer 3. T cell receptor 4. Accessory cell 3D2E?$dX
5. Fc¦Å receptor 6. Cytokine ]C) 4
¶þ¡¢ ÎÊ´ðÌâ 3`k;a1Z#O'
1. ÃâÒßϵͳÖУ¬ÄÄЩϸ°ûÄÜÌØÒì»ò·ÇÌØÒâÐÔµØÉ±É˰Ðϸ°û£¬ÊÔ·Ö±ð¼òÊöɱÉË×÷ÓõIJ»Í¬Ìص㡣 '#k0a,<N
2. ¸ù¾ÝT¡¢Bϸ°û±íÃæ±êÖ¾µÄ²»Í¬£¬¿ÉÒÔÓ¦ÓÃÄÄЩÃâÒßѧ¼¼Êõ¼ø±ðÕâÁ½Ààϸ°û£¬¼òÊöÓйصÄʵÑéÔÀí£¿ eM+!Y>8Y
3. ÔÚIVÐͳ¬Ãô·´Ó¦ÖУ¬ÖÂÃôTϸ°ûÊÍ·ÅÄÄЩÁܰÍÒò×Ó²ÎÓëÃâÒßËðÉË£¬ÏêÊöÆä×÷ÓûúÀí¡£ o_'p3nD
4. ÊÔÊöHLA¸´ºÏÌåµÄÒÅ´«Ìص㼰ÕâÐ©ÌØµãµÄÉúÎïѧÒâÒ壿 78/Zk}I
]
5. ºÎνµ¥¿Ë¡¿¹Ì壿ÏêÊöÆäÔÚ»ù´¡ÓëÁÙ´²Ò½Ñ§ÖеÄÓ¦ÓᣠRj4|Q:XG
$C `;fA
L31HGH2l
*NG+L)g
Rb.SY{}C
<TP=oq?I/
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾ÅÈýÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ R=|{n'n$0|
9M:O0
) s
Nd;Ku6
רҵ¿Î ÃâÒßѧ DK$s&zf
Ò»¡¢ ·Òë²¢½âÊÍÏÂÁÐÃû´Ê O<,\^[x
1¡¢ Complement receptor type ¢ñ 2¡¢ Serologically defined antigen "T|PS6R~
3¡¢ Transfer factor 4¡¢ Immunotoxin 5¡¢ Perforin 4y+< dw
6¡¢ Arthus reaction 7¡¢ Network theoty 8.Lymphocyte transformation test lR(+tj)9uO
9. Hybridoma technic 10.Mitogen 8@tPm$
11.Dentritic cell 12.Immunoproliferation 6*3.S
GUY
¶þ¡¢ »Ø´ðÏÂÁÐÎÊÌâ #H:7@
1¡¢ ÍÌÊÉϸ°û¶Ôϸ¾úµÄÍÌÊɹý³Ì°üÀ¨ÄöÖ÷Òª½×¶Î£¬ÊÔÏêÊöÖ®¡£ 'JRvP!]
2¡¢ ÊÔÊöIL-2µÄϸ°ûÀ´Ô´¹¦Äܼ°ÁÙ´²Ó¦ÓᣠaXoVy&x=
3¡¢ Ò©Îï»ò»¯Ñ§ÊÔ¼ÁÒýÆðµÄÒ©ÕîÊôÓÚʲôÐͳ¬Ãô·´Ó¦£¬ÊÔÊöÆä»úÀí¡£ |fHV2Y`:g
4¡¢ ÌåÄÚµÄÃâÒß·Ö×Ó°üÀ¨Äļ¸ÀࣿÊÔ¼òÊö¸÷ÀàÃâÒß·Ö×ÓµÄÖ÷Òª¹¦ÄÜ¡£ lk( }-
5¡¢ ºÎνÃâÒß±ê¼Ç¼¼Êõ£¿Ö÷ÒªÓÐÄļ¸ÀàÃâÒß±ê¼Ç¼¼Êõ£¿ÊÔ·Ö±ð¼òÊöËüÃǵÄÖ÷ÒªÔÀí¡£ OEkN(wF
0`[wpZ
z[3L2U~6
0DJ+I
< Pky9o;
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾ÅËÄÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ [_Qa9e
*exS6@N]
5Er2}KZJv,
רҵ¿Î ÃâÒßѧ 28UU60
Ò»¡¢ Ãû´Ê½âÊÍ HlH64w2^R
1¡¢ ³Ù·¢Ðͱä̬·´Ó¦Tϸ°û 2¡¢ C1ÒÖÖÆÎï P7{gfiB
3¡¢ ¼¯Âä´Ì¼¤Òò×Ó 4¡¢ ¿¹ÔÌá³Ê×÷Óà 4x 8)gE
5¡¢ HIAÓë¼²²¡µÄ¹ØÁª 6¡¢ Ë«¹¦ÄÜ¿¹Ìå 7¡¢ ÃâÒßÄÍÊÜ Yj6*NZ*
¶þ¡¢ ÎÊ´ðÌâ ~,i-8jl,
1¡¢ TÁܰÍϸ°û¾ßÓÐÄÄЩ±íÃæ±êÖ¾£¿ÊÔÊö¸÷±íÃæ±êÖ¾µÄÉúÎïѧ×÷Óü°/»òÒâÒå¡£ [D<1CF
2¡¢ ÊÔÊöÒÆÖ²ÅųⷴӦµÄÃâÒßÓ¦´ð¹ý³Ì¼°²ÎÓëÅųⷴӦµÄÖÂÃôÁܰÍϸ°ûºÍЧӦÎïÖÊ¡£ 1*@'-mj
3¡¢ ºÎνϸ°ûÒò×Ó£¿¼òÊöÆä¹²Í¬Ìص㼰ÓëÁÙ´²µÄ¹ØÏµ¡£ &M.66O@
4¡¢ ºÎνÁܰÍϸ°ûÔÓ½»Áö¼¼Êõ£¬ÊÔÊöÆäÔÀí¼°ÒâÒå¡£ 5) pj]S!]-
5¡¢ ºÎνÉúÎïËØ-Ç׺ÍËØÏµÍ³£¿ÊÔÊöÆäÓ¦ÓÃÓÚÃâÒß±ê¼Ç¼¼ÊõµÄÔÀí£¬ÒÔABC·¨ÎªÀý˵Ã÷Ö®¡£ `#;e)1
s=0BMPDgm
3ZXQoC '
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾ÅÎåÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ _N{RVeO
CD~z=vlK-
Y7*U:I+N
רҵ¿Î ÃâÒßѧ O vk_\On
Ò»¡¢ ·Òë²¢½âÊÍÏÂÁÐÃû´Ê d~1gMz+)
1¡¢ SmIg 2¡¢ Graft-versus-host reaction GVHR %nV]ibp2)
3¡¢ Immunocompent cell ICC 4¡¢ Tumor-associated antigen TAA d~JKH&x<
5¡¢ Cytokine 6¡¢ Immune tolerance 7¡¢ Biological responsw modifier BRM +P
cmJ
¶þ¡¢ ÎÊ´ðÌâ @CZ
T
1¡¢ ÃâÒßϵͳÄÚÆðɱÉËЧӦµÄϸ°ûÓÐÄÄЩ£¿ÊÔ¼òÊöÆäɱÉËЧӦµÄÌØµã¡£ t+1 %RyKFB
2¡¢ ºÎν¿¹ÌåµÄ¶àÑùÐÔ£¿¿¹ÌåµÄ¶àÑùÐÔ±íÏÖÔÚÄÄЩ·½Ã棿¼òÊö²úÉú¿¹Ìå¶àÑùÐÔµÄÔÀí¡£ B(n{e53 9f
3¡¢ ÊÔÊö¢òÐÍÓë¢óÐͳ¬Ãô·´Ó¦·¢Éú»úÖÆµÄÒìͬµã¡£ A^y|J`k|
4¡¢ ºÎνMHC£¿ÊÔ¼òÊöÆä¹¦ÄÜ¡£ \xnWciQ#{
5¡¢ ºÎνÃâÒß±ê¼Ç¼¼Êõ£¿Ö÷ÒªÓÐÄļ¸ÀàÃâÒß±ê¼Ç¼¼Êõ£¬ÒÔø±ê¼Ç¼¼ÊõΪÀý¼òÊöÆäÖ÷ÒªÔÀí¡£ Ljx(\Cm
Wb?8j M
rjp-Fw~1w
98uV6b~g
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾ÅÁùÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ VrxQc qPr`
y&?6FY
WYEKf9}
רҵ¿Î ÃâÒßѧ 5yzv|mrx
Ò»¡¢ ·Òë²¢½âÊÍÏÂÁÐÃû´Ê :uK?4
1. IgSF 2. Fc 3. Flow cytometry 4. Adhesion molecule enSXP~9w
5. Autogous mixed lymphoyte reaction /7t>TYip!
¶þ¡¢ ÎÊ´ðÌâ 2M68CE
1. ÊÔÊöÍâÀ´TD¿¹Ô½øÈë»úÌåÓÕµ¼¿¹Ìå²úÉúµÄÈ«¹ý³Ì¡£ ~1W x=
2. ºÎνϸ°ûÒò×Ó£¿¼òÊöIL-2µÄ¼ì²â·½·¨¼°ÆäÔÀí¡£ q gLaa
3. ¼òÊö¿¹¶ÀÌØÐÍÍøÂçµÄµ÷¿Ø×÷ÓᣠdVi!Q@y+
4. ÃâÒßÓ¦´ð¶Ô»úÌåÓкÎÀûº¦¹ØÏµ£¿ 9+{G8$Ai
]jmL]Ny^
* Of4o
(+FfB"3]
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾ÅÆßÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ 5[YDZ7g"~
n3D;"a3
b{]z
wpf
רҵ¿Î ÃâÒßѧ 7lBAxqr2
;[u%_
2VE9}%i
Ò»¡¢ ·Òë²¢½âÊÍÏÂÁÐÃû´Ê
1][S#H/?
1. Idiotupe 2. Opsonization 3. Epitope 4. Immunologic tolerance
hnc@
5. Delayed type hypersensitivity 6T#+V37
¶þ¡¢ ÎÊ´ðÌâ <\
}KT*Xp
1. ÊÔÊö²¹Ì徵伤»î;¾¶ÓëÅÔ·¼¤»î;¾¶µÄÒìͬ¡£ "vyNxZE
2. ¼òÊö¿¹ÌåµÄ»ù±¾½á¹¹£¨ÒÔIgGΪÀý£©Ó빦ÄÜ¡£ 0QOBL'{7)
3. ¼òÊöHLAÓëҽѧµÄ¹ØÏµ¡£ S7L=#+Z
4. ÊÔÊöµ¥ºË/¾ÞÊÉϸ°ûÔÚÃâÒßÓ¦´ðÖеÄ×÷ÓᣠkAC&S!n
5. ¼òÊöÃâÒßÓ¦´ðÖи÷ÖÖÀàÐ͵Äϸ°û¶¾×÷ÓᣠvDxe/x%
li 6%)
?)1{)Erf8x
=MLcm^b
w$`5g
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾Å°ËÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ [ zEUH:9D
26k LhFS
\DD0s8
רҵ¿Î ÃâÒßѧ ZObhF#Y9
Ò»¡¢ ·Òë²¢½âÊÍÏÂÁÐÃû´Ê -cSP_1
1. hypersensitivity 2. cluster of differentiation +[tE ^`-F
3. adhesion molecules 4. supper antigen 5. split tolerance frT]5?{
¶þ¡¢ ÎÊ´ðÌâ ;F~LqC$
1. ºÎνϸ°ûÒò×Ó£¿ÊÔÊöϸ°ûÒò×ÓµÄÖ÷ÒªÉúÎïѧ»îÐÔ¡£ ;Mpy#yIU.
2. ¼òÊöMHC¿¹ÔµÄ·Ö×ӽṹ¼°Æä×éÖ¯·Ö²¼¡£ |Clut~G
3. ÊÔÊöÐØÏÙÒÀÀµÐÔ¿¹ÔÒýÆðÌåÒºÃâÒßÓ¦´ðµÄÈ«¹ý³Ì£¨°üÀ¨³õ´ÎÃâÒßÓ¦´ðºÍÔÙ´ÎÃâÒßÓ¦´ð£©¡£ KFvQ
4. Ϊʲô˵²¹Ì弤»î;¾¶Ö÷Òª²ÎÓëÌìÈ»ÃâÒߣ¿ÊÔÊö²¹ÌåÊÇÈçºÎ¾¹ýÅÔ·;¾¶¶ø±»¼¤»îµÄ¡£ H+ 0$tHi
5. Ϊʲô¿¹Ä³Ò»Ï¸°ûÒò×ÓÊÜÌåµÄµ¥¿Ë¡¿¹ÔÌ壬ÓбíÏÖ³öÊÜÌå·â±Õ×÷Ó㬶øÓеÄÔò±íÏÖ³öÊÜÌå´Ì¼¤×÷Óã¿ v(-{=
*':
U]vYV
PV/77{'
f/Hm{<BY
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾Å¾ÅÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ ?$6Y2
רҵ¿Î ÃâÒßѧ 8qu2iPOcZ
Ò»¡¢ Ãû´Ê½âÊÍ %y|)=cm[
1. ¿¹ÔÐÔ 2. ÃâÒßÇòµ°°×³¬¼Ò×å 3. ¶ÀÌØÐÍ 4. ¿¹Ô¾ö¶¨×å d_)o
5. GVHR SOi*SwQ8
¶þ¡¢ ÎÊ´ðÌâ 8rMX9qTO@
1. Á½ÖÖ²¹Ì弤»î;¾¶µÄµ÷½ÚÒò×ÓÓÐÄÄЩ£¿±È½ÏËüÃÇÁ½ÖÖ;¾¶ÖеÄ×÷ÓᣠpSr{>;bN
2. ¢òÐͳ¬Ãô·´Ó¦µÄ»úÀíÌØµãÊÇʲô£¿¾Ù³öÈý¸ö¢òÐͳ¬Ãô·´Ó¦µÄÀý×Ó¡£ -"h;uDz|z
3. ÊÔÊöϸ°ûÒò×ÓµÄ×÷ÓÃÌØµã¡£ hDcEGU_
4. Bcell½éµ¼µÄÌåÒºÃâÒßÓ¦´ðµÄ¹ý³Ì¡£ 'C
~y5j
5. MPSµÄÃâÒßѧ¹¦ÄÜ¡£ `>?ra-
ALNc
'MW!
%T)oCjM[\
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾Å¾ÅÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ ;M_o)OS3
B]Y}Hu
H*Kj3NgY
רҵ¿Î ÃâÒßѧ 20iq2
Ò»¡¢Ãû´Ê½âÊÍ ld^=#]g
1. ÃâÒßÇòµ°°×µÄ¶ÀÌØÐÍ 2. 𤸽·Ö×Ó 3. ÃâÒßÇòµ°°×³¬¼Ò×å %ix)8+Eb
4. ¸ÉÈÅËØ 5. HLAµÄ¶à̬ÐÔ 6. ÐØÏÙÒÀÀµÐÔ¿¹Ô 7. ÃâÒßÄÍÊÜ h|h>u
^@
8. ËÙ·¢Ðͳ¬Ãô·´Ó¦ 9. µ¥¿Ë¡¿¹Ìå 10. ²¹Ì徵伤»î;¾¶
{e[c
11. »ìºÏÁܰÍϸ°û·´Ó¦ 12. ÓÐË¿·ÖÁÑ &/uu)v
Èý¡¢ ÎÊ´ðÌâ i2sN3it
1. ÊÔ¼òÊö¾ÞÊÉϸ°ûÌá³ÊTD¿¹ÔµÄ¹ý³Ì¡£ O=$~O\}b
2. ÊÔ¼òÊöÒÆÖ²ÎËÞÖ÷·´Ó¦µÄ·¢Éú»úÖÆ GF>'\@Th
3. ÊÔÊö²¹ÌåµÄÖ÷ÒªÉúÎïѧ×÷Óà tX@_fYb
4. ÒÔIgGΪÀý£¬ÊÔÊöÃâÒßÇòµ°°×·Ö×ӵĻù±¾½á¹¹ {.De4]ANh
5. ÊÔÊöTϸ°ûµÄÖ÷Òª±íÃæ±êÖ¾¼°¹¦ÄÜ u6MzRC
;w%*M}`5
W ]Nv33i
[
;Wl+zw
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾Å¾ÅÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ ]6{*^4kX
xw3YK!$sIF
UY <e&Npo
רҵ¿Î ÃâÒßѧ <6fv1d+v
Ò»¡¢Ãû´Ê½âÊÍ +{/*z
1. Ig¶ÀÌØÐÍ 2. SAg 3. 𤸽·Ö×Ó 4. CSF 5. IgSF 6. Tϸ°û»î»¯µÄ´Ì¼¤·Ö×Ó a9T@$:
7. HLAÓë¼²²¡µÄ¹ØÁª 8. ELISA 9. ÁܰÍϸ°ûµÄ±íÃæ±êÖ¾ TzntO9P+
Èý¡¢ ÎÊ´ðÌâ _^'I
1. ¼òÊöTÁܰÍϸ°ûµÄ·ÖÀ༰¹¦ÄÜ£¿ OI?K/rn
2. ¼òÊöHLAÍ»±äÌåµÄ»ùÒò×é³É¼°HLAµÄ¹¦ÄÜ£¿ [ e8x&{L-_
3. ¼òÊö»úÌå¶ÔÍâÔ´ÐÔ¿¹Ô£¨ÒìÎԣ©µÄ´¦Àí£¬ÈçIgÌá³Ê¹ý³Ì£¿ 9{$<0,?
4. ¼òÊö²¹ÌåÁ½ÖÖ¼¤»î;¾¶µÄ»ù±¾¹ý³Ì£¬²¢±È½Ï¶þÕßÒìͬ£¿ +8#_59;x
5. ¼òÊöAIDSÖÐCD4+ϸ°û¼õÉٵĻúÖÆ£¿ r.
T<j.\
9&2Vm;F_
\|U l]1pO8
h[?O+Z^
(C\hVy2X?N
99Äê˶ʿÑо¿ÉúÃâÒßѧÊÔÌâ {XWZ<OjG
Ò»¡¢Ãû´Ê½âÊÍ @0eHS
+
2¡¢ HLAµÄ¶à̬ÐÔ 3¡¢ 𤸽·Ö×Ó 4¡¢ ¶ÀÌØÐÍ 5¡¢ ¿¹ÔëÄתÔËÎï E%'~'[Q
6¡¢ Ig³¬¼Ò×å 7¡¢ µòÍö 8¡¢ ÓÐË¿·ÖÁÑÔ 9¡¢ CD4·Ö×Ó d)[;e()
10¡¢ ³¬Ãô·´Ó¦ 11¡¢ ×ÔÉíÃâÒß²¡ Pf$pt
¶þ¡¢ ÎÊ´ðÌâ m "M("%
1¡¢ ÊÔÊöÍâÔ´ÐÔ¿¹ÔºÍÄÚÔ´ÐÔ¿¹ÔÌá³ÊµÄ¹ý³Ì¡£ :KKa4=5L
2¡¢ ÊÔÊöBϸ°û½éµ¼µÄÔÙ´ÎÃâÒßÓ¦´ðµÄ¹ý³Ì¡£ #CnHf
3¡¢ ÊÔÊö·Ö×ÓˮƽµÄÃâÒßµ÷½Ú¡£ <n:}kQTT
4¡¢ ÊÔÊö»ñµÃÐÔÃâÒßȱÏÝ×ÛºÏÕ÷£¨AIDS£©µÄ·¢²¡»úÖÆ¡£ s
(0*
gxT4PQDy
2000Äê˶ʿÑо¿ÉúÃâÒßѧÊÔÌâ U^.4Hy&D
Ò»¡¢ Ãû´Ê½âÊÍ e.*%K!(
1¡¢ µ÷Àí×÷Óà 2¡¢ 𤸽·Ö×Ó 3¡¢ ³¬¿¹Ô 4¡¢ ÃâÒßȱÏݲ¡ 2~*Ez!.3
5¡¢ FasÓëFasL 6¡¢ µ¥¿Ë¡¿¹Ìå 7¡¢ ÃâÒßÄÍÊÜ {66fG53x
8¡¢ ÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£© 9¡¢ Ö×ÁöÏà¹Ø¿¹Ô£¨TAA£© w]_zp?\^
}
10¡¢ ÒõÐÔÑ¡Ôñ NB7Y{)
w
¶þ¡¢ ÎÊ´ðÌâ M^7MU}5w
1¡¢ ºÎνϸ°ûÒò×Ó£¿ÊÔÊöϸ°ûÒò×ӵĹ²Í¬Ìص㣿 5I,gBT|B
2¡¢ ºÎνAPC¼°ÆäÖÖÀࣿ¼òÊöÍâÔ´ÐÔ¿¹ÔµÄÈÜøÌåÌá³Ê;¾¶£¿ ph}j[Co
3¡¢ ¼òÊöϸ°ûÃâÒßÓ¦´ðµÄÁ½ÀàЧӦϸ°ûµÄЧӦ»úÖÆ£¿Ï¸°ûÃâÒßµÄÉúÎïѧÒâÒ壿 )%X;^(zKM
4¡¢ ºÎνMHC£¿¼òÊöMHCµÄ¹¦ÄÜ£¿ IF +i3#$
5¡¢ ºÎν×ÔÉíÃâÒß²¡£¿¼òÊö×ÔÉíÃâÒß²¡µÄ×éÖ¯ËðÉË»úÖÆ£¿. bpkwn<7-
NJ MJ
S|zW^|YU
&(a(W22O
ͬ¼ÃÒ½¿Æ´óѧ2000Äê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ IhiGP
{
$2MAZGJV
`Ci4YDaz;k
רҵ¿Î ÃâÒßѧ vMs;>lhtg
Ò»¡¢½«ÏÂÁÐÓ¢Óïµ¥´Ê·Òë³ÉÖÐÎIJ¢Ãû´Ê½âÊÍ P(
SZ68
1. Cytokines 2. adhesion molecules 3. graft versus host reaction O3N_\B:
4. immunologic tolerance 5. Opsonization 0fs$#j
Èý¡¢ ÎÊ´ðÌâ RkuuogZ
1. ʲôÊÇMHC£¿ÊÔÊöMHC-¢òÀà·Ö×ӵĽṹ¡¢¸÷²¿Î»¹¦ÄÜ£¬MHC-¢òÀà·Ö×ÓµÄ×éÖ¯·Ö²¼¼°ÆäÃâÒßѧ×÷Óᣠf{lZKfrp
2. ÓÐÄÄÈý´ú¿¹Ì壿ÊÔÊö¿¹Ì壨IgG£©µÄ»ù±¾½á¹¹¡¢¸÷²¿Î»¹¦Äܼ°ÕâÈý´ú¿¹ÌåµÄÌØÐÔ¡£ MqKye8h9f
3. ʲôÊÇ×ÔÉíÃâÒß²¡£¿ÊÔÊöÆä·¢²¡»úÖÆ¡£ -#29xRPk
4. ÃâÒßϵͳɱÉ˰Ðϸ°ûµÄ·½Ê½¼°ÏàӦϸ°ûºÍ·Ö×ÓÓÐÄÄЩ£¿ÊÔÊöTc½éµ¼µÄϸ°ûÃâÒßÓ¦´ð¡£ sLcFt1
5. »úÌåµÄÃâÒßϵͳΪʲô¿ÉÒÔʶ±ð×Ô¼ººÍÒ켺£¿ÆäÖ÷Òª»úÖÆÊÇʲô£¿ xAwf49N~
a45ss7
1#
t6`N]?V
CkRX>)=py
*]x*B@RF
@-#T5?
»ªÖпƼ¼´óѧͬ¼ÃҽѧԺ DJQglt}~
y_}SK6{
}'=h4yI
2001ÄêÕÐÊÕ˶ʿÑо¿ÉúÈëѧרҵ¿Î¿¼ÊÔÊÔÌâ bQaoMZB
¿¼ÊÔ¿ÆÄ¿£ºÒ½Ñ§ÃâÒßѧ 4Z)DDz-}V
Ò»¡¢ ½âÊÍÏÂÁÐÃû´Ê |z^pL1Z]5
1. C3b½éµ¼µÄµ÷Àí×÷Óà 2.Tϸ°û¼¤»îµÄµÚ¶þÐźÅ3.Th1ϸ°û 4.HLAµÄ¶à̬ÐÔ z]Acs
5.C1ÒÖÖÆÎï 6.TCR¦Ã¦ÄTϸ°û7.³Ù·¢Ðͳ¬Ãô·´Ó¦ 8.Ç÷»¯ÐÔϸ°ûÒò×Ó9.ÃâÒßÇòµ°°×µÄÀà±ðת»¯ 10.ÔìѪ¸Éϸ°û ;t]|15]u
11.»î»¯ÓÕµ¼µÄϸ°ûËÀÍö \,sg)^w@
¶þ¡¢ Çë»Ø´ðÏÂÁÐÎÊ´ð ,fnsE^}.U
1. ºÎνµ¥¿Ë¡¿¹Ì壬¼òÊöÆäÖÆ±¸ÔÀí¡£ hN(L@0)
2. ¼òÊöTϸ°ûÔÚÐØÏÙÄڵķ¢Óý¹ý³Ì¡£ =V|Nn0E
3. ÃâÒßϸ°û±íÃæÖ÷ÒªÓÐÄļ¸Àà±íÃæ¿¹ÔºÍ±íÃæÊÜÌ壬¼òÊö¸÷Àà·Ö×ÓµÄÖ÷Òª¹¦ÄÜ¡££¨HLA¡¢CD¡¢AM¡¢CKR¡¢CR¡¢MitogenR¡¢TCR¡¢BCR¡¢FcR£© IX?ZbtdX$`
4. ÊԱȽÏTCR¸´ºÏÌåºÍBCR¸´ºÏÌå½á¹¹Ó빦ÄܵÄÒìͬ¡£ OCHm;
5. ÊԱȽϳ¬¿¹ÔÓëÆÕͨ¿¹ÔµÄÒìͬ¡£ HPa|uDVv
g]`bnZ7
y,<$X.>QO|
Q-zdJt
o@dy:AR
74zSP/G'
»ªÖпƼ¼´óѧͬ¼ÃҽѧԺ Sue
6+p
2001ÄêÕÐÊÕ˶ʿÑо¿ÉúÈëѧµ¥¶À¿¼ÊÔÊÔÌâ \/,g VT
¿¼ÊÔ¿ÆÄ¿£ºÃâÒßѧ GEtbs+ [
v[D&L_
Ò»¡¢ Ãû´Ê½âÊÍ & z gPN8u
1. ¿¹Ô³ÊµÝ 2. µ÷Àí×÷Óà 3. ³Áµí·´Ó¦ 4. ×ÔÉíÃâÒß 6{7 3p@
5. GVHR 6. ÔìѪ¸Éϸ°û 7. ¿Ë¡ѡÔñѧ˵ 8. Ir»ùÒò E|,30Z+
9. ³¬Ãô·´Ó¦ 10. ³¬¿¹Ô ja7
5c~RUw
¶þ¡¢ÎÊ´ðÌâ cDO:'-
11. ¼òÊö²¹ÌåµÄÅÔ·¼¤»î;¾¶ wA r~<
12. ¼òÊöT¡¢Bϸ°ûÌØÕ÷µÄ²îÒì U"B.:C2
13. ¼òÊöT¡¢Bϸ°û¿¹Ô¾ö¶¨´ØµÄ²îÒì va>"#;37
14. ΪʲôÃâÒßÇòµ°°×¾ßÓп¹ÔÐÔ£¿ÊÔÊöÃâÒßÇòµ°°×µÄ¿¹ÔÐÔ¡£ e;;):\p4
15. ʲôÊÇÖ×Áö¿¹Ô£¿ÊÔÊö»úÌåÕë¶ÔÖ×Áö¿¹Ô²úÉú¿¹Ö×ÁöÃâÒßÓ¦´ðµÄ»úÖÆ¡£ M1(9A>|nF
!u%9;>T7